Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-37442524

RESUMO

Radioiodine therapy represents a fundamental pillar in the routine adjuvant therapy of patients with high-risk differentiated thyroid carcinoma. However, a non-negligible percentage of these patients will develop iodine refractoriness, showing a worse prognosis, as well a lower survival, which demonstrates a clear need to explore different therapeutic approaches. Iodine refractory patient treatment continues to be a challenge, currently having different novel therapeutic options that should be known by the different specialties related to differentiated thyroid carcinoma (DTC). The aim of this work is to review iodine refractory thyroid carcinoma treatment, focusing especially on the definition of iodine refractoriness, highlighting its importance due to its high mortality, and introducing the different therapeutic options available for these patients.


Assuntos
Adenocarcinoma , Iodo , Neoplasias da Glândula Tireoide , Humanos , Adenocarcinoma/tratamento farmacológico , Iodo/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Prognóstico , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/radioterapia
2.
Radiologia (Engl Ed) ; 65(1): 12-21, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36842781

RESUMO

OBJECTIVE: To contribute our results to increase the scientific evidence about the use of radioembolization in the management of patients with hepatocellular carcinoma. MATERIAL AND METHODS: This retrospective review included 53 patients with hepatocellular carcinoma treated with radioembolization at our center. Patients were classified according to the BCLC algorithm in detail according to their Child-Pugh functional status. We analyzed survival using the Kaplan-Meier method. We used Cox regression analysis to determine clinically significant parameters, including the doses administered in the parameters studied. RESULTS: Patients ranged in age from 28 to 86 years (mean, 60 years). A total of 61 procedures were done. The mean activity administered was 2.8GBq (0.7-6.4GBq), with a mean dose of 229.9Gy (74-425.9Gy) administered in the tumor. Progression-free survival was 6.7 months and overall survival was 12.8 months. Differences in disease-free survival according to BCLC and Child-Pugh classification were not significant (p=0.848 and p=0.252, respectively). The clinical parameters that were significantly different with respect to overall survival were bilirubin levels (p<0.001), pretreatment transaminase levels (AST) (p=0.022), Child-Pugh subclassification (p=0.003), and dose administered in the tumor (p=0.001). Only one patient had a severe adverse reaction, developing posttreatment liver failure resulting in death. CONCLUSIONS: Radioembolization is safe and efficacious in the treatment of patients with hepatocellular carcinoma. Liver function and the doses received by the tumor are key parameters for the efficacy of treatment. The increase in the scientific evidence supports the inclusion of this technique in treatment guidelines.


Assuntos
Carcinoma Hepatocelular , Embolização Terapêutica , Neoplasias Hepáticas , Humanos , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/radioterapia , Neoplasias Hepáticas/radioterapia , Intervalo Livre de Doença , Estudos Retrospectivos , Embolização Terapêutica/métodos
3.
Artigo em Inglês | MEDLINE | ID: mdl-34920969

RESUMO

This continuing education aims to present in a clear and easy-to-understand way, the biology of neuroendocrine tumors (NETs), the characteristics of somatostatin receptors, the selection of patients for radiolabelled peptide therapy (PRRT), the inclusion criteria to benefit from treatment with the minimum possible adverse effects, the administration protocol, follow-up and response evaluation. The functional imaging studies necessary to explore the biology of the tumor and to individualize the treatment are also carried out, and constitute the cornerstone for the development of teragnosis. Clinical trials are being developed to better define the position of PRRT within the broad therapeutic options, and among the future perspectives, there are several lines of research to improve the objective response rate and survival with PRRT, focused on the development of new agonists and somatostatin receptor antagonists, new radionuclides and radiosensitizing combination therapies. In conclusion, PRRT is a great therapeutic, well-tolerated and safe tool with generally mild and self-limited acute side effects, that must be sequenced at the best moment of the evolution of the disease of patients with NET. Candidate patients for PRRT should always be evaluated by a multidisciplinary clinical committee.


Assuntos
Tumores Neuroendócrinos , Compostos Heterocíclicos com 1 Anel , Humanos , Tumores Neuroendócrinos/radioterapia , Radioisótopos , Receptores de Somatostatina
4.
Rev Esp Med Nucl ; 29(3): 114-21, 2010.
Artigo em Espanhol | MEDLINE | ID: mdl-20399539

RESUMO

OBJECTIVE: Re-evaluate the effective dose (E) of typical nuclear medicine procedures using the new ICRP-103 weighting factors and the latest dosimetry data and relate E with Background Equivalent Radiation Time (BERT). MATERIAL AND METHODS: Effective dose associated with radiopharmaceuticals and nuclear medicine procedures has been calculated for the following ages: adult, 15, 10, 5 and 1 year. Dosimetry data have been extracted from ICRP-106, ICRP-80, ICRP-53 and/or manufacturer's brochure. RESULTS: The relationship of the data of effective dose associated with radiopharmaceuticals and explorations is shown. The new tissue weighting factors result in a decreased value of the effective dose, except in cases that particularly affect the breast, in which it increases. The effective dose associated with nuclear medicine procedures is in the range 0.1-60 mSv. BERT ranges from a few days to 20 years. The effective dose associated to tests in children is generally higher than the effective dose for an adult. CONCLUSIONS: The results shown in this paper are an updated collection of effective dose values for commonly used radiopharmaceuticals in nuclear medicine. Expressing the effective dose equivalent time in units of natural radiation helps to explain issues associated with radiation exposure to patients and healthcare personnel.


Assuntos
Algoritmos , Relação Dose-Resposta à Radiação , Medicina Nuclear/estatística & dados numéricos , Radiometria/estatística & dados numéricos , Adulto , Fatores Etários , Criança , Humanos , Especificidade de Órgãos , Doses de Radiação , Radioisótopos/administração & dosagem , Padrões de Referência
5.
Rev Esp Med Nucl ; 29(1): 25-8, 2010.
Artigo em Espanhol | MEDLINE | ID: mdl-19819594

RESUMO

INTRODUCTION: Carcinoid tumor is a rare neuroendocrine neoplasm with different locations, the most frequent ones during the pediatric age being the appendix and lung. Scintigraphy with (111)In-DTPA-d-Phe(1)-octreotide has led to an importance advance in the diagnosis of extension in carcinoid tumor patients. We present three pediatric patients with bronchial carcinoid studied with somatostatin analogue scintigraphy (SSRS). CLINICAL CASES: The first patient (9 years) was studied using the SSRS after surgery due to carcinoid tumor in the right lower lobe in which tumor remains was observed (this being clearer in the tomography study). The second patient (10 years) presented due to endobronchial tumor in the left lower lobe together with atelectasis of the LUL and emphysema of the LLL. Radiology imaging techniques suggested the differential diagnosis between the endobronchial carcinoid tumor or plasma cells or foreign body gramuloma. The SSRS showed an abnormal deposit of activity in the left hemithorax consisted with carcinoid tumor. No other areas suggesting metastasis were observed. After the surgery (endobronchial resection), new controls with SSRS showed absence of disease. The third patient (12 years) came after a lobectomy (RUL) due to bronchial carcinoid. The SSRS did not show any abnormal areas of activity. In the subsequent control (3 months), a deposit of activity was observed in the middle third of the right hemithorax, after which a lobectomy was performed (RLL and ML) that showed small remains of neuroendocrine carcinoid. Subsequent controls were negative. CONCLUSION: The SSRS has demonstrated great utility in the diagnosis, follow-up and staging of pediatric patients, carriers of neuroendocrine carcinoid tumors.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias Brônquicas/diagnóstico por imagem , Tumor Carcinoide/diagnóstico por imagem , Neoplasias Pulmonares/diagnóstico por imagem , Proteínas de Neoplasias/análise , Receptores de Somatostatina/análise , Neoplasias Brônquicas/química , Neoplasias Brônquicas/cirurgia , Tumor Carcinoide/química , Tumor Carcinoide/cirurgia , Criança , Diagnóstico Diferencial , Feminino , Humanos , Radioisótopos de Índio , Neoplasias Pulmonares/química , Neoplasias Pulmonares/cirurgia , Masculino , Octreotida/análogos & derivados , Pneumonectomia , Cuidados Pós-Operatórios , Complicações Pós-Operatórias/etiologia , Atelectasia Pulmonar/etiologia , Enfisema Pulmonar/etiologia , Cintilografia , Compostos Radiofarmacêuticos , Reoperação
6.
Radiologia (Engl Ed) ; 2020 Nov 27.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33257052

RESUMO

OBJECTIVE: To contribute our results to increase the scientific evidence about the use of radioembolization in the management of patients with hepatocellular carcinoma. MATERIAL AND METHODS: This retrospective review included 53 patients with hepatocellular carcinoma treated with radioembolization at our center. Patients were classified according to the BCLC algorithm in detail according to their Child-Pugh functional status. We analyzed survival using the Kaplan-Meier method. We used Cox regression analysis to determine clinically significant parameters, including the doses administered in the parameters studied. RESULTS: Patients ranged in age from 28 to 86 years (mean, 60 years). A total of 61 procedures were done. The mean activity administered was 2.8 GBq (0.7-6.4 GBq), with a mean dose of 229.9Gy (74-425.9Gy) administered in the tumor. Progression-free survival was 6.7 months and overall survival was 12.8 months. Differences in disease-free survival according to BCLC and Child-Pugh classification were not significant (p=0.848 and p=0.252, respectively). The clinical parameters that were significantly different with respect to overall survival were bilirubin levels (p<0.001), pretreatment transaminase levels (AST) (p=0.022), Child-Pugh subclassification (p=0.003), and dose administered in the tumor (p=0.001). Only one patient had a severe adverse reaction, developing posttreatment liver failure resulting in death. CONCLUSIONS: Radioembolization is safe and efficacious in the treatment of patients with hepatocellular carcinoma. Liver function and the doses received by the tumor are key parameters for the efficacy of treatment. The increase in the scientific evidence supports the inclusion of this technique in treatment guidelines.

7.
Rev Esp Med Nucl ; 28(5): 242-5, 2009.
Artigo em Espanhol | MEDLINE | ID: mdl-19922841

RESUMO

We present a clinical case of a 54-year-old woman that was admitted in our hospital with the diagnosis of fever of unknown origin. All the laboratory tests and imaging techniques did not manage to establish the fever's aetiology until a (67)Ga-citrate scan was performed and kidney uptake was observed, which lead to the clinical suspicion of drug-induced interstitial nephritis. The renal biopsy confirmed the diagnosis. This finding allowed corticoid therapy and cure.


Assuntos
Citratos , Febre de Causa Desconhecida/etiologia , Gálio , Nefrite Intersticial/complicações , Nefrite Intersticial/diagnóstico por imagem , Compostos Radiofarmacêuticos , Feminino , Humanos , Pessoa de Meia-Idade , Cintilografia
8.
Rev Esp Med Nucl Imagen Mol ; 36(2): 116-119, 2017.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27793633

RESUMO

In a patient with a differentiated thyroid cancer the standard treatment protocol to be followed is surgery, ablation of thyroid remnants with 131Iodine (131I), and TSH suppression. However, the treatment with 131I is not effective in some cases, and it no longer becomes a therapeutic option due to cell de-differentiation with loss of 131I uptake. Systemic treatment can be used as other options, although patients are not always responsive; thus, the disease may progress and therapeutic options may run out. Endocrine tumours may express somatostatin receptors,and this characteristic has been used, not only for diagnosis, but also for their treatment through somatostatin analogue labelling with radioactive isotopes. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin receptors expression, treated with 177Lu-DOTATATE, showing an excellent clinical and analytical response.


Assuntos
Adenocarcinoma Folicular/radioterapia , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/secundário , Neoplasias Hepáticas/radioterapia , Neoplasias Hepáticas/secundário , Lutécio/uso terapêutico , Octreotida/análogos & derivados , Compostos Organometálicos/uso terapêutico , Radioisótopos/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Adenocarcinoma Folicular/sangue , Adenocarcinoma Folicular/tratamento farmacológico , Adenocarcinoma Folicular/cirurgia , Idoso , Antibióticos Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/sangue , Neoplasias Ósseas/diagnóstico por imagem , Neoplasias Ósseas/tratamento farmacológico , Terapia Combinada , Doxorrubicina/uso terapêutico , Everolimo/uso terapêutico , Feminino , Bócio Nodular/complicações , Bócio Nodular/cirurgia , Humanos , Indazóis , Radioisótopos do Iodo/uso terapêutico , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/tratamento farmacológico , Niacinamida/análogos & derivados , Niacinamida/uso terapêutico , Octreotida/uso terapêutico , Cuidados Paliativos , Compostos de Fenilureia/uso terapêutico , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Pirimidinas/uso terapêutico , Sorafenibe , Sulfonamidas/uso terapêutico , Tireoglobulina/sangue , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia
9.
Actas Urol Esp ; 41(1): 23-31, 2017.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27422080

RESUMO

OBJECTIVE: To validate the technique of selective sentinel node biopsy for diagnosing and staging intermediate to high-risk prostate cancer by comparing the technique with conventional extended lymphadenectomy (eLFD) in a prospective, longitudinal comparative study. METHODS: We applied the technique to 45 patients. After an intraprostatic injection of 99mTc-nanocolloid and preoperative single-photon emission computed tomography (SPECT/CT), we extracted the sentinel lymph nodes, guided by a portable Sentinella® gamma camera and a laparoscopic gamma-ray detection probe. The eLFD was completed to establish the negative predictive value of the technique. RESULTS: SPECT/CT showed radiotracer deposits outside the eLFD territory in 73% of the patients and the laparoscopic gamma probe in 60%. The mean number of active foci per patient was 4.3 in the SPECT/CT and 3.2 in the laparoscopic gamma probe. The mean number of extracted sentinel lymph nodes was 4.3 (0-14), with 26% outside the eLFD territory. The lymph nodes were metastatic in 10 patients (22%), 6/40 (15%) when the prostatectomy was the primary treatment. In all cases with metastatic lymph nodes, there was at least one positive sentinel node. Metastatic sentinel lymph nodes were found outside the eLFD territory in 3/10 patients (30%). The sensitivity was 100%, the specificity was 94.73%, the positive predictive value was 81.81%, and the negative predictive value was 100%. CONCLUSION: Selective sentinel node biopsy is superior to eLFD for diagnosing lymph node involvement and can avoid eLFD when metastatic sentinel lymph nodes are not found (85%), with the consequent functional advantages.


Assuntos
Excisão de Linfonodo/métodos , Nomogramas , Prostatectomia , Neoplasias da Próstata/patologia , Neoplasias da Próstata/cirurgia , Biópsia de Linfonodo Sentinela , Humanos , Laparoscopia , Estudos Longitudinais , Masculino , Estudos Prospectivos , Prostatectomia/métodos
10.
Rev Esp Med Nucl ; 25(3): 166-71, 2006.
Artigo em Espanhol | MEDLINE | ID: mdl-16762270

RESUMO

OBJECTIVE: Relative renal function (RRF) quantification based on dimercaptosuccinic acid (DMSA) uptake is an established method for determining differential renal function. An abnormal kidney size may lead to an alteration in its RRF value, although it has no dysfunction. Therefore, it is useful to correct RRF values taking into account relative renal volumes, thus obtaining the normalized relative renal function (NRRF). The feasibility of the method used for volume correction, differences with respect to usual quantification and different normality intervals were studied. MATERIAL AND METHODS: A total of 187 DMSA renal scintigraphies (130 children and 57 adults) were studied. RRF was quantified and volume corrected to obtain NRRF. Patients were classified as normal or pathological using various normality intervals for NRRF. A second classification was performed depending on how the diagnostic changed after volume correction. RESULTS: An increase of pathological diagnosis was observed after volume correction, mainly in children. Using an intermediate estimation for the normality interval, 53% of the initially pathological diagnosis for children may be caused simply by different renal volumes. CONCLUSIONS: NRRF provides complementary information to RRF and helps to distinguish between a smaller kidney and a really hypofunctioning one in cases with abnormal RRF.


Assuntos
Testes de Função Renal/métodos , Rim/fisiopatologia , Succímero , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Rim/patologia , Nefropatias/diagnóstico , Nefropatias/patologia , Nefropatias/fisiopatologia , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Valores de Referência , Fatores Sexuais , Succímero/farmacocinética
14.
Rev Esp Med Nucl ; 20(5): 381-5, 2001 Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-11470073

RESUMO

Gastrinomas are uncommon tumors which are difficult to locate. They are often located in the head of the pancreas. About two-thirds of them are malignant, their growth is slow and they usually metastasize in the liver. In about 25% of cases, the Zollinger-Ellison (Z-E) syndrome is included in the multiple endocrine neoplasm type 1 syndrome (MEN 1).A 14-year old male patient presenting an episode of abdominal perforation which required emergency surgery is reported. The abdominal ultrasonography, CT scan and magnetic resonance revealed a single lesion in the left liver lobe, suggesting metastasis. Significantly increased levels of serum gastrin suggested a diagnosis of Z-E syndrome. A study with 111In-octreotide was required to locate the primary tumor and evaluate its extent. The scintigraphy showed only one abnormal uptake focus in the left liver lobe. Post-surgery scintigraphy studies revealed the presence of metastatic adenopathies which were removed after a second surgery. No pathologic findings were observed in the last nuclear medicine study. The somatostatin receptor scintigraphy is the most sensitive method to locate primary gastrinomas and to assess the tumoral dissemination in patients with Z-E Syndrome.


Assuntos
Gastrinoma/diagnóstico por imagem , Índio , Neoplasias Hepáticas/diagnóstico por imagem , Octreotida , Síndrome de Zollinger-Ellison/diagnóstico por imagem , Dor Abdominal/etiologia , Adolescente , Tumor Carcinoide/diagnóstico , Cistos/diagnóstico , Diagnóstico Diferencial , Úlcera Duodenal/complicações , Úlcera Duodenal/diagnóstico , Gastrinoma/complicações , Gastrinoma/patologia , Hematemese/etiologia , Humanos , Hepatopatias/diagnóstico , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/patologia , Metástase Linfática , Imageamento por Ressonância Magnética , Masculino , Cintilografia , Tomografia Computadorizada por Raios X , Ultrassonografia , Síndrome de Zollinger-Ellison/complicações
15.
Rev Esp Med Nucl ; 19(7): 500-3, 2000 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-11171508

RESUMO

The case of a patient who came to the Nuclear Medicine Department for a bone scintigraphy to rule out bone metastasis because of a lung neoplasm is presented. Some days before, the patient had suffered a right brain infarction. 99mTc-MDP uptake could be seen in the infarction area. Different mechanisms of 99mTc phosphates deposition in tissues other than bones are reviewed in this article.


Assuntos
Infarto Encefálico/diagnóstico por imagem , Compostos Radiofarmacêuticos/farmacocinética , Medronato de Tecnécio Tc 99m/farmacocinética , Idoso , Humanos , Masculino , Cintilografia
17.
Rev Esp Med Nucl ; 17(1): 40-4, 1998.
Artigo em Espanhol | MEDLINE | ID: mdl-9609843

RESUMO

Four cases are presented of ectopic thyroid tissue in adult women who underwent for thyroid study for different motives. Radioisotopic uptake was absent in the usual thyroid location. Thyroid function was normal in every case and no psychomotor abnormalities were present. In one case, echography revealed an atrophic thyroid in the usual location in association with thyroid ectopy. The literature of thyroid ectopy was reviewed and the preponderant role of radioisotopic scan is underlined, together with thyroid echography in the imaging diagnosis of neck masses.


Assuntos
Coristoma , Pescoço , Glândula Tireoide , Adulto , Coristoma/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Pescoço/diagnóstico por imagem , Cintilografia , Testes de Função Tireóidea , Glândula Tireoide/diagnóstico por imagem , Ultrassonografia
18.
Rev Esp Med Nucl ; 18(3): 190-6, 1999 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-10431067

RESUMO

OBJECTIVE: To ascertain whether a given level of antimyosin monoclonal antibody (AMA) uptake in the endomyocardial biopsy (EMB) can identify patients with rejection. MATERIAL AND METHOD: 186 examinations were performed on 65 patients (8 women and 57 men) with orthotopic heat transplant (HT): Mean age 51 +/- 13 years. There were 3 examinations per patient (range 1-6). The studies were conducted 13 to 880 days after the HT. The C/p uptake indexes were obtained according to the Carrió y cols. method and the results were compared with the biopsy findings. Rejection was considered to be when the biopsy showed at least one site of necrosis. RESULTS: 1) We analyzed the C/P index in accordance with the post-HT interval and with the degree of rejection obtained by EMB. No group showed any significant differences between the patients with an without rejection (p > 0,05). 2) We applied a variable threshold based on post-HT interval, using an exponential curve defined on the basis of the interval of the values corresponding to patients without rejection and good progress compared with that of the rejection patients. This approach also did not contribute any improvement compared to the use of a fixed threshold due to the significant overlay of the values for patients with and without rejection. 3) Finally, we analyzed the individual evolution of the C/P indexes for each patient in terms of time. In patients whose clinical progress was good, the C/P indexes were observed to drop progressively over time. In those whose clinical progress was poor, abrupt increases in the index values were observed. CONCLUSION: We were unable to differentiate significantly between patients with and without rejection in EMB using fixed and variable thresholds of the C/P index. However, the different patterns of evolution for each patient provide information on the lack of complications and could be used as a follow-up technique.


Assuntos
Anticorpos Monoclonais , Rejeição de Enxerto/diagnóstico por imagem , Transplante de Coração , Miosinas/imunologia , Adolescente , Adulto , Biópsia , Interpretação Estatística de Dados , Endocárdio/patologia , Feminino , Rejeição de Enxerto/patologia , Transplante de Coração/patologia , Humanos , Radioisótopos de Índio , Masculino , Pessoa de Meia-Idade , Miocárdio/patologia , Necrose , Cintilografia , Sensibilidade e Especificidade , Fatores de Tempo
19.
Rev Esp Med Nucl ; 19(5): 361-4, 2000 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-11062113

RESUMO

Acute cholecystitis is an uncommon disease in childhood. Few cases in patients under 10 years of age have been found in literature. An eight-year old male patient with no history of interest who had acute acalculous cholecystitis was reported. Ultrasonographic and isotopic studies led to the diagnosis and control of the patient's evolution.


Assuntos
Colecistite/diagnóstico por imagem , Doença Aguda , Criança , Humanos , Masculino , Cintilografia , Compostos Radiofarmacêuticos , Ácido Dietil-Iminodiacético Tecnécio Tc 99m
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA